ArticlePloS one2010
The Salmonella genomic island 1 is specifically mobilized in trans by the IncA/C multidrug resistance plasmid family.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed.
- Conjugative transfer inhibition of IncA and IncC plasmids by SGI1-like elements via relaxosome assembly interference.Nucleic acids research · 2026Article
- Global phylogeography and genomic characterization ofmSystems · 2025Article
- IncC plasmid genome rearrangements influence the vertical and horizontal transmission tradeoff inAntimicrobial agents and chemotherapy · 2024Article
- Surface exclusion of IncC conjugative plasmids and their relatives.PLoS genetics · 2024Article
- Two birds with one stone: SGI1 can stabilize itself and expel the IncC helper by hijacking the plasmid parABS system.Nucleic acids research · 2024Article
- Mechanism of antibacterial resistance, strategies and next-generation antimicrobials to contain antimicrobial resistance: a review.Frontiers in pharmacology · 2024Review
- Mobilome-driven partitions of the resistome inmSystems · 2023Article
- Conjugative IncC Plasmid Entry Triggers the SOS Response and Promotes Effective Transfer of the Integrative Antibiotic Resistance Element SGI1.Microbiology spectrum · 2023Article
- Evolution and Emergence of Antibiotic Resistance in Given Ecosystems: Possible Strategies for Addressing the Challenge of Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2022Review
- Genomic characterization of multidrug-resistantMicrobial genomics · 2022Article
- Structural analysis of VirD4 a type IV ATPase encoded by transmissible plasmids ofFrontiers in artificial intelligence · 2022Article
- Overview ofFrontiers in microbiology · 2022Article
- The Dynamics of the Antimicrobial Resistance Mobilome ofFrontiers in microbiology · 2022Review
- Evolutionary Pathways and Trajectories in Antibiotic Resistance.Clinical microbiology reviews · 2021Article
- Salmonella Genomic Island 1 requires a self-encoded small RNA for mobilization.Molecular microbiology · 2021Article
- Crucial role of Salmonella genomic island 1 master activator in the parasitism of IncC plasmids.Nucleic acids research · 2021Article
- Genomic islands targeting dusA in Vibrio species are distantly related to Salmonella Genomic Island 1 and mobilizable by IncC conjugative plasmids.PLoS genetics · 2021Article
- Sequence analysis of tyrosine recombinases allows annotation of mobile genetic elements in prokaryotic genomes.Molecular systems biology · 2021Article
- ComprehensiveMicrobial genomics · 2021Article
- IncC helper dependent plasmid-like replication of Salmonella Genomic Island 1.Nucleic acids research · 2021Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Salmonella genomic island 1 (SGI1) is a Salmonella enterica-derived integrative mobilizable element (IME) containing various complex multiple resistance integrons identified in several S. enterica serovars and in Proteus mirabilis. Previous studies have shown that SGI1 transfers horizontally by in trans mobilization in the presence of the IncA/C conjugative helper plasmid pR55. METHODOLOGY/PRINCIPAL
findingsHere, we report the ability of different prevalent multidrug resistance (MDR) plasmids including extended-spectrum β-lactamase (ESBL) gene-carrying plasmids to mobilize the multidrug resistance genomic island SGI1. Through conjugation experiments, none of the 24 conjugative plasmids tested of the IncFI, FII, HI2, I1, L/M, N, P incompatibility groups were able to mobilize SGI1 at a detectable level (transfer frequency <10(-9)). In our collection, ESBL gene-carrying plasmids were mainly from the IncHI2 and I1 groups and thus were unable to mobilize SGI1. However, the horizontal transfer of SGI1 was shown to be specifically mediated by conjugative helper plasmids of the broad-host-range IncA/C incompatibility group. Several conjugative IncA/C MDR plasmids as well as the sequenced IncA/C reference plasmid pRA1 of 143,963 bp were shown to mobilize in trans SGI1 from a S. enterica donor to the Escherichia coli recipient strain. Depending on the IncA/C plasmid used, the conjugative transfer of SGI1 occurred at frequencies ranging from 10(-3) to 10(-6) transconjugants per donor. Of particular concern, some large IncA/C MDR plasmids carrying the extended-spectrum cephalosporinase bla(CMY-2) gene were shown to mobilize in trans SGI1. CONCLUSIONS/SIGNIFICANCE: The ability of the IncA/C MDR plasmid family to mobilize SGI1 could contribute to its spread by horizontal transfer among enteric pathogens. Moreover, the increasing prevalence of IncA/C plasmids in MDR S. enterica isolates worldwide has potential implications for the epidemic success of the antibiotic resistance genomic island SGI1 and its close derivatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.